Literature DB >> 22391760

Initial dose of vancomycin based on body weight and creatinine clearance to minimize inadequate trough levels in Japanese adults.

N Maki1, A Ohkuchi, Y Tashiro, M R Kim, M Le, T Sakamoto, S Matsubara, Y Hakamata.   

Abstract

Our aims were to elucidate the factors that affected vancomycin (VCM) serum trough levels and to find the optimal initial dose based on creatinine clearance (CrCl) and body weight (BW) to minimize inadequate trough levels in a retrospective observational study among Japanese adults. One hundred and six inpatients, in whom VCM trough levels were measured after completing the third dosing, were consecutively recruited into our study in a tertiary hospital. We considered the frequency of <30% as low. In the generalized linear model, initial VCM total daily dose, CrCl, and BW were independent risk factors of VCM trough levels. In patients with CrCl ≥30 and <50 mL/min, 1 g/day yielded low frequencies of a trough level of ≥20 mcg/mL, regardless of BW. In patients with CrCl ≥50 mL/min, 2 g/day yielded low frequencies of a trough level of <10 mcg/mL in patients weighing <55 kg, but not in patients weighing ≥55 kg. Optimal VCM initial total daily dose may be 1 g/day in patients with CrCl ≥30 and <50 mL/min regardless of BW and 2 g/day in patients weighing <55 kg with CrCl ≥50 mL/min among Japanese adults.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391760     DOI: 10.1007/s10096-012-1593-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  16 in total

1.  Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus.

Authors:  Brian T Tsuji; Michael J Rybak; Kerry L Lau; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

Review 3.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

4.  Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients.

Authors:  Eytan Cohen; Alexander Dadashev; Moshe Drucker; Zmira Samra; Ethan Rubinstein; Moshe Garty
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

Review 5.  Vancomycin ototoxicity and nephrotoxicity. A review.

Authors:  G R Bailie; D Neal
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

6.  Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Richard P Novick; Lata Venkataraman; Christine Wennersten; Paola C DeGirolami; Mitchell J Schwaber; Howard S Gold
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

7.  Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters.

Authors:  John E Murphy; David E Gillespie; Carol V Bateman
Journal:  Am J Health Syst Pharm       Date:  2006-12-01       Impact factor: 2.637

Review 8.  Vancomycin revisited.

Authors:  F V Cook; W E Farrar
Journal:  Ann Intern Med       Date:  1978-06       Impact factor: 25.391

9.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.

Authors:  R C Moellering; D J Krogstad; D J Greenblatt
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391

View more
  4 in total

Review 1.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

2.  Evaluation of a protocol for vancomycin administration in critically patients with and without kidney dysfunction.

Authors:  Savino Spadaro; Angela Berselli; Alberto Fogagnolo; Maurizia Capuzzo; Riccardo Ragazzi; Elisabetta Marangoni; Sara Bertacchini; Carlo Alberto Volta
Journal:  BMC Anesthesiol       Date:  2015-06-27       Impact factor: 2.217

3.  Development of a decision flowchart to identify the patients need high-dose vancomycin in early phase of treatment.

Authors:  Ryo Yamaguchi; Hiroko Kani; Takehito Yamamoto; Takehiro Tanaka; Hiroshi Suzuki
Journal:  J Pharm Health Care Sci       Date:  2022-01-04

Review 4.  Weight-based dosing in medication use: what should we know?

Authors:  Sheng-Dong Pan; Ling-Ling Zhu; Meng Chen; Ping Xia; Quan Zhou
Journal:  Patient Prefer Adherence       Date:  2016-04-12       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.